Vol. 8, Issue 6 (2019)

Aims & Objectives: The purpose of the study was to assess the safety and efficacy of Ferric Carboxymaltose (FCM) in anaemic patients during pregnancy in the department of Obstetrics and Gynaecology at Rajah Muthiah Medical College & Hospital (RMMCH), a 1400 bedded multi-specialty tertiary care teaching hospital.

Methodology: This is a Prospective Observational Study conducted on total of 41 pregnant anaemic patients who were included in the study of 3 months period. In our study, the majority of the subjects falls in the age group 24-29 (37%) with a mean gestational age 34 ± 2 weeks and the average weight of the patients is 58 ± 3 kilograms.

Results: Outcome of our study shows a significant increase in the mean Hb level and mean ferritin levels. At pre-infusion stage the mean Hb level and mean ferritin levels of 41 patients were recorded as 8.58 ± 0.37 and 78.21 ± 26.41 respectively. Whereas Hb and Ferritin levels increased to 10.85 ± 0.57 and 151.46 ± 16.21; 11.82 ± 0.55 and 195.78 ± 6.94; 11.87 ± 0.58 and 204.07 ± 5.56 after 3 weeks of post infusion, at delivery and at 6 weeks of post infusion respectively. As part of our study, DDD/41 patients were calculated according to the DTC (Drugs and Therapeutic Committee-guide) with reference from WHO Recommended ATC Classification and found that DDD/41 patients were 1.6g.

Conclusions: Our study suggests that therapeutic doses of FCM IV can be recommended for treatment of IDA during pregnancy. It is simple to use and causes significant increase in Hb and ferritin levels. It does not affect the health of the mothers as well as babies. Only a mild and quickly reversible local adverse reaction such as pain and rash at injection site were recorded from patient case sheet and patient interview.